WOCKPHARMA2023-10-012023-12-31 WOCKPHARMA2023-10-012023-12-31 WOCKPHARMA2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member WOCKPHARMA2023-12-31 WOCKPHARMA2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member WOCKPHARMA2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532300 WOCKPHARMA NA Wockhardt Limited Equity 2023-04-01 2024-03-31 2024-02-14 2024-02-05 INR Crores Third quarter 11:45:00 14:25:00 2024-02-14 2024-02-14 Not applicable Single segment Pharmaceuticals 2023-10-01 2023-12-31 Unaudited Consolidated 7010000000.00 80000000.00 7090000000.00 1600000000.00 1500000000.00 -80000000.00 1520000000.00 770000000.00 550000000.00 2100000000.00 7960000000.00 -870000000.00 0.00 -870000000.00 30000000.00 -40000000.00 -10000000.00 0.00 -860000000.00 0.00 0.00 0.00 0.00 -860000000.00 670000000.00 -190000000.00 -830000000.00 -30000000.00 -270000000.00 80000000.00 720000000.00 5 -5.75 -5.75 0.00 0.00 -5.75 -5.75 0.00 0.00 0.00 1. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on February 14, 2024. The results have been subjected to limited review by the Statutory Auditors of the Company.2. The Consolidated Results relate to Wockhardt Limited ('the Company' or 'the Holding Company') and its Subsidiaries (together constitute ‘the Group’) and are prepared by applying Ind AS 110 - Consolidated Financial Statements 3. During the previous year ended March 31, 2023, subsequent to the settlement agreement with the State of Texas on February 8, 2022, the Group had agreed for an early payment schedule for the settlement of the liability. Pursuant to this revision, Group had recorded an additional cost of Rs.11 crores due to unwinding of the discount (basis the original payment schedule) and has disclosed this as 'Exceptional items'.4. During the previous year ended March 31, 2023, the Group has provided/ incurred loss of Rs. 123 crores w.r.t property, plant and equipment sold/ held for sale, Rs. 17 crores for inventory, Rs. 80 crores for claims incurred/ expected claims from customers and Rs. 13 crores for other costs pursuant to the restructuring of business in USA and has disclosed these as 'Exceptional items'5. The Company had accounted for a contract asset of Rs. 50 crores pursuant to a contract manufacturing agreement The Customer is yet to fulfill its contractual obligations and commitments. Though, the Company is pursuing various options and taking necessary actions related to this matter, given the uncertainty, Company had provided for this contract asset in the previous year and this was disclosed as 'Exceptional items'. Company had also purchased certain specific inventory for this contract which has not been used. Company is continuing to evaluate alternate options to liquidate/ utilize such inventory, pending which, during the current period, the Company has made a provision of Rs. 14 crores for such inventory basis the current assessment and information available as on date. This expenditure is also reported as ‘Exceptional items’.6. During the quarter ended December 31, 2023, the Company has allotted 6,900 (Year to date: 13,150) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options. 7. Key Financials on Standalone basis: Particulars 3 MONTHS ENDED 31/12/2023 Unaudited 3 MONTHS ENDED 30/09/2023 Unaudited 3 MONTHS ENDED 31/12/2022 Unaudited 9 MONTHS ENDED 31/12/2023 Unaudited 9 MONTHS ENDED 31/12/2022 Unaudited YEAR ENDED 31/03/2023 Audited Total Income 293 266 300 816 877 1,139 Loss before tax (74) (107) (55) (296) (224) (513) Loss after tax (74) (107) (55) (296) (167) (466) Note: The unaudited standalone results have been filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are available on the Stock Exchanges websites (www.nseindia.com and www.bseindia.com ) and also on the Company's website www.wockhardt.com. 8. The Group is exclusively into Pharmaceutical business Segment. 9. For List of Subsidiaries as on December 31, 2023 please refer Annexure. 10.EPS for the quarter and nine months ended December 31, 2023 is not annualised. Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 20980000000.00 310000000.00 21290000000.00 4760000000.00 4050000000.00 -100000000.00 4720000000.00 2320000000.00 1650000000.00 6150000000.00 23550000000.00 -2260000000.00 -140000000.00 -2400000000.00 140000000.00 410000000.00 550000000.00 0.00 -2950000000.00 0.00 0.00 0.00 0.00 -2950000000.00 460000000.00 -2490000000.00 -2940000000.00 -10000000.00 -2560000000.00 70000000.00 720000000.00 5 -20.40 -20.40 0.00 0.00 -20.40 -20.40 0.00 0.00 0.00 Exchange Fluctuations loss, net 150000000.00 other expense 1950000000.00 Exchange Fluctuations loss, net 20000000.00 other expense 6130000000.00 Items that will not be reclassified to Profit or Loss -(charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset) 10000000.00 Items that will not be reclassified to Profit or Loss -(charge) / credit (consisting of re-measurement of net defined benefit (liability) / asset) 20000000.00 10000000.00 20000000.00 0.00 0.00 Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations) (Continued operations) 660000000.00 Items that will be reclassified to Profit or Loss - (charge) / credit (Consisting of Exchange differences on translating the financial statements of foreign operations) (Continued operations) 440000000.00 660000000.00 440000000.00 0.00 0.00